Cargando…

Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome

BACKGROUND: Until now, there is non-specific treatment, and exploring early and novel biomarkers to determine the disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS) would be of importance for clinician to take systematic and timely intervention. This study observed the ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Du, Hong, Bai, Xue-Fan, Wang, Xiao-Yan, Zhang, Ying, Jiang, Hong, Wang, Ping-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831831/
https://www.ncbi.nlm.nih.gov/pubmed/29490629
http://dx.doi.org/10.1186/s12879-018-3005-0
_version_ 1783303207982727168
author Li, Jing
Du, Hong
Bai, Xue-Fan
Wang, Xiao-Yan
Zhang, Ying
Jiang, Hong
Wang, Ping-Zhong
author_facet Li, Jing
Du, Hong
Bai, Xue-Fan
Wang, Xiao-Yan
Zhang, Ying
Jiang, Hong
Wang, Ping-Zhong
author_sort Li, Jing
collection PubMed
description BACKGROUND: Until now, there is non-specific treatment, and exploring early and novel biomarkers to determine the disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS) would be of importance for clinician to take systematic and timely intervention. This study observed the expression of plasma sCD138, a soluble component shedding from the glycocalyx (GCX) to the circulating blood, and evaluated its predictive value on disease severity and prognosis of HFRS. METHODS: One hundred and seventy-six patients with HFRS who were treated at our center between January 2011 and December 2013 were randomly enrolled in this study. The patients were divided into a mild-type group, a moderate-type group, a severe-type group and a critical-type group according to the HFRS criteria for clinical classification. Thirty-five blood samples from healthy subjects were obtained as the controls. The concentrations of sCD138 were detected using enzyme linked immunosorbent assay (ELISA). The levels of prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), white blood cells (WBC), platelets (PLT), glucose (GLU), blood urea nitrogen (BUN) and serum creatinine (Scr) in the samples were routinely tested. The levels of sCD138 among the different types were compared; the correlation among sCD138 and the laboratory parameters mentioned above were analyzed. The predictive effectiveness for prognosis of sCD138 was evaluated using the receiver operating characteristic (ROC) curve analysis. RESULTS: Except for the mild-type, the levels of sCD138 in the moderate-, severe- and critical-type patients during the acute stage were significantly higher than that of the convalescent stage and the control (P<0.05). With the aggravation of the disease, the levels of sCD138 during the acute stage had an increasing tendency, while demonstrated no significant difference among the moderate-, severe- and critical-type patients (P>0.05). sCD138 was negatively correlated with Fib, PLT and ALB, and was positively correlated with WBC and AST (P<0.05). sCD138 demonstrated predictive effectiveness for prognosis with the area under the curve (AUC) of 0.778 (P<0.001). CONCLUSION: Dynamic detection of plasma sCD138 might be benefit to evaluating the disease severity and prognosis of the patients with HFRS.
format Online
Article
Text
id pubmed-5831831
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58318312018-03-05 Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome Li, Jing Du, Hong Bai, Xue-Fan Wang, Xiao-Yan Zhang, Ying Jiang, Hong Wang, Ping-Zhong BMC Infect Dis Research Article BACKGROUND: Until now, there is non-specific treatment, and exploring early and novel biomarkers to determine the disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS) would be of importance for clinician to take systematic and timely intervention. This study observed the expression of plasma sCD138, a soluble component shedding from the glycocalyx (GCX) to the circulating blood, and evaluated its predictive value on disease severity and prognosis of HFRS. METHODS: One hundred and seventy-six patients with HFRS who were treated at our center between January 2011 and December 2013 were randomly enrolled in this study. The patients were divided into a mild-type group, a moderate-type group, a severe-type group and a critical-type group according to the HFRS criteria for clinical classification. Thirty-five blood samples from healthy subjects were obtained as the controls. The concentrations of sCD138 were detected using enzyme linked immunosorbent assay (ELISA). The levels of prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), white blood cells (WBC), platelets (PLT), glucose (GLU), blood urea nitrogen (BUN) and serum creatinine (Scr) in the samples were routinely tested. The levels of sCD138 among the different types were compared; the correlation among sCD138 and the laboratory parameters mentioned above were analyzed. The predictive effectiveness for prognosis of sCD138 was evaluated using the receiver operating characteristic (ROC) curve analysis. RESULTS: Except for the mild-type, the levels of sCD138 in the moderate-, severe- and critical-type patients during the acute stage were significantly higher than that of the convalescent stage and the control (P<0.05). With the aggravation of the disease, the levels of sCD138 during the acute stage had an increasing tendency, while demonstrated no significant difference among the moderate-, severe- and critical-type patients (P>0.05). sCD138 was negatively correlated with Fib, PLT and ALB, and was positively correlated with WBC and AST (P<0.05). sCD138 demonstrated predictive effectiveness for prognosis with the area under the curve (AUC) of 0.778 (P<0.001). CONCLUSION: Dynamic detection of plasma sCD138 might be benefit to evaluating the disease severity and prognosis of the patients with HFRS. BioMed Central 2018-03-01 /pmc/articles/PMC5831831/ /pubmed/29490629 http://dx.doi.org/10.1186/s12879-018-3005-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Jing
Du, Hong
Bai, Xue-Fan
Wang, Xiao-Yan
Zhang, Ying
Jiang, Hong
Wang, Ping-Zhong
Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title_full Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title_fullStr Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title_full_unstemmed Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title_short Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
title_sort study on expression of plasma scd138 in patients with hemorrhagic fever with renal syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831831/
https://www.ncbi.nlm.nih.gov/pubmed/29490629
http://dx.doi.org/10.1186/s12879-018-3005-0
work_keys_str_mv AT lijing studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT duhong studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT baixuefan studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT wangxiaoyan studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT zhangying studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT jianghong studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome
AT wangpingzhong studyonexpressionofplasmascd138inpatientswithhemorrhagicfeverwithrenalsyndrome